Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements


Download results of this page


Refine by:

Content type

Project (10)

Advanced search

Search projects and results

Results 1 - 10 of 10
Results/page:
1
Mobile Filovirus Nucleic Acid Test
ID: 115848
Start date: 2015-02-01, End date: 2017-04-30
We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics...
Programme: H2020-EU.3.1.7.13.
Record Number: 209448
Last updated on: 2017-04-05
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
ID: 115842
Start date: 2015-03-01, End date: 2018-02-28
The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates...
Programme: H2020-EU.3.1.7.13.
Record Number: 209443
Last updated on: 2017-03-27
Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes
ID: 115890
Start date: 2015-09-03, End date: 2017-12-31
Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major adaptations to current paradigms of bringing medicines to patients are required in order to realize that potential and to address important...
Programme: H2020-EU.3.1.7.13.
Record Number: 209455
Last updated on: 2017-03-27
Remote Assessment of Disease and Relapse in Central Nervous System Disorders
ID: 115902
Start date: 2016-04-01, End date: 2021-03-31
Background: Long term conditions require monitoring of patients, traditionally conducted in the clinic, to monitor treatment effects, adverse events and disease course. This can be inefficient and cumbersome – clinic visits may be too infrequent to identify individuals at...
Programme: H2020-EU.3.1.7.13.
Record Number: 209453
Last updated on: 2017-03-27
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen
ID: 115854
Start date: 2014-12-01, End date: 2019-11-30
The overall aim of the EBOVAC programme is to assess the safety and efficacy/effectiveness, if feasible, of a novel prime-boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies. This will be done via phase I...
Programme: H2020-EU.3.1.7.13.
Record Number: 209452
Last updated on: 2017-03-27
Ebola Virus: Modern Approaches for developing  bedside Rapid Diagnostics
ID: 115843
Start date: 2015-02-01, End date: 2018-01-31
The current Ebola Virus Disease (EVD) outbreak has caused more than 5000 deaths within a few months in West Africa (Guinea, Sierra Leone and Liberia being the most severely affected countries), including numerous healthcare workers. It is now a serious public health crisis of...
Programme: H2020-EU.3.1.7.13.
Record Number: 209451
Last updated on: 2017-03-27
Ultra-Fast Molecular Filovirus Diagnostics
ID: 115844
Start date: 2015-02-01, End date: 2017-08-31
There is an urgent need for fast and accurate diagnostic tests in future Ebola outbreak situations. The rapid diagnosis of Ebola Virus Disease (EVD) during early and late stage of infection is a decisive step for risk assessment and for guidance to physicians to take the...
Programme: H2020-EU.3.1.7.13.
Record Number: 209449
Last updated on: 2017-03-27
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment.
ID: 115847
Start date: 2014-12-01, End date: 2017-11-30
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment.The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These partners...
Programme: H2020-EU.3.1.7.13.
Record Number: 209447
Last updated on: 2017-03-27
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II
ID: 115861
Start date: 2014-12-01, End date: 2017-11-30
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.This will be done by:1. Carrying out translational studies to link vaccine elicited immune responses in humans...
Programme: H2020-EU.3.1.7.13.
Record Number: 209445
Last updated on: 2017-03-27
Manufacturing and Development for Rapid Access Ebola Vaccine (EBOMAN)
ID: 115850
Start date: 2015-03-10, End date: 2017-11-30
This topic response (Topic 2: Manufacturing Capability) forms part of an integrated proposal to address the urgent unmet needs of accelerating the development of an Ebola vaccine. To help facilitate this main goal additional activities will be performed; the generation of...
Programme: H2020-EU.3.1.7.13.
Record Number: 209444
Last updated on: 2017-03-27
1
List retrieved on: 2017-04-30
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top